Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04874233 · ClinicalTrials.gov registry record · Phase 2
Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers
A Phase 2 study of NASH - Nonalcoholic Steatohepatitis, sponsored by Rivus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT04874233: Completed Phase 2 study of NASH - Nonalcoholic Steatohepatitis, sponsored by Rivus Pharmaceuticals.
NCT04874233 is a Phase 2 study of NASH - Nonalcoholic Steatohepatitis that has completed, run by Rivus Pharmaceuticals. The registered enrollment target is 80 participants, below the 259-participant average among 28 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04874233, a Phase 2 study of NASH - Nonalcoholic Steatohepatitis, has completed, sponsored by Rivus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2a, randomized, parallel-group, placebo-controlled, double-blind, repeated-dose study to evaluate the safety and efficacy of three oral dose levels of HU6 compared to placebo over the course of 61 days in subjects with high BMI and evidence of elevated liver fat.
Primary Outcome
Percentage of Change from Baseline in Liver Fat Content as Assessed by MRI-PDFF at Day 61
Conditions Studied
Interventions
- DRUG Placebo
- DRUG HU6
Study Locations (1)
Minnesota
- Prism Clinical Research - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-04-19 |
| Est. Completion | 2021-12-15 |
| Phase | Phase 2 |
What the finished NCT04874233 record still lists
NCT04874233 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 259-participant average among 28 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (69% lower).
The record links to 1 condition, with NASH - Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04874233 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04874233 about?
NCT04874233 is a clinical study titled "Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers". This is a Phase 2a, randomized, parallel-group, placebo-controlled, double-blind, repeated-dose study to evaluate the safety and efficacy of three oral dose levels of HU6 compared to placebo over the course of 61 days in subjects with high BMI and evidence of elevated liver fat.
What is the current status of trial NCT04874233?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2021-04-19. Estimated completion is 2021-12-15.
What conditions does trial NCT04874233 study?
This clinical trial studies the following conditions: NASH - Nonalcoholic Steatohepatitis.
What interventions are being tested in trial NCT04874233?
The interventions under investigation include: Placebo (DRUG), HU6 (DRUG).
Who is sponsoring clinical trial NCT04874233?
This trial is sponsored by Rivus Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04874233 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NASH - Nonalcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04874233's enrollment target sits among peer trials
80 15th of 28 higher than 14 of 28 other NASH - Nonalcoholic Steatohepatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NASH - Nonalcoholic Steatohepatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)
ACTIVE NOT RECRUITING · Phase 2
-
Statins for the Treatment of NASH
ACTIVE NOT RECRUITING · Phase 2
-
Tocotrienol Against the Progression of End Stage Liver Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial
COMPLETED · Phase 2
-
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI